Celsion Corporation (NASDAQ:CLSN)

CAPS Rating: 1 out of 5

A biotechnology company dedicated to furthering the development and commercialization of treatment systems for cancer and other diseases using focused heat energy in combination with other therapeutic devices or heat-activated genes.

Results 1 - 14 of 14

Recs

1
Member Avatar zzlangerhans (99.85) Submitted: 4/29/2014 11:20:32 PM : Outperform Start Price: $3.34 CLSN Score: -35.72

Playing Celsion on CAPS (as well as trading it in real life) has nothing to do with science. Instead, it relates to understanding the human qualities of greed and gullibility and the way that they interact with fear and manipulation. Thermodox failed its phase III trial, unequivocally. If Thermodox ever becomes a commercially successful therapeutic, it will be the most unlikely development I have seen in all my years of following biopharma. Everything that is currently happening with Thermodox has happened a hundred times before with failed drugs that continue to go through the charade of development because company management doesn't have better options than collecting their inflated salaries for a few more years. Meanwhile, assorted market reprobates flood to the void left by fleeing sellsiders and flog the eviscerated husk of the stock to other momentum sharks and gullible newbies and retirees. The end result is that the stock takes on a life of its own long after the company's reason for existing has become moot. This green thumb means I think the share price will go up more than the benchmark in the near future, and nothing else.

Recs

0
Member Avatar karlsmq (< 20) Submitted: 5/30/2013 2:01:41 PM : Outperform Start Price: $8.56 CLSN Score: -95.32

THEIR PATENTS

Recs

0
Member Avatar gupper2 (< 20) Submitted: 5/24/2013 6:49:27 PM : Outperform Start Price: $4.82 CLSN Score: -72.19

Big advancements in cancer research

Recs

0
Member Avatar HoldThatWinner (30.69) Submitted: 2/8/2013 11:16:54 AM : Outperform Start Price: $5.26 CLSN Score: -90.87

Nice Fat Round J Lo Double Bottom Booty at $1.13.

Don't Mind if I do.

Recs

2
Member Avatar Imhilion (< 20) Submitted: 1/1/2013 11:01:37 PM : Underperform Start Price: $37.53 CLSN Score: +135.99

Terrible pump and dump

Recs

0
Member Avatar fmgklg (< 20) Submitted: 1/1/2013 4:49:54 PM : Outperform Start Price: $37.53 CLSN Score: -135.99

Phase III results will be great because this is not a drug, it is a delivery system of an existing drug that will greatly help the oncology treatment of many cancers.

Recs

0
Member Avatar SamsaricSufferer (< 20) Submitted: 7/4/2012 8:14:51 PM : Outperform Start Price: $16.38 CLSN Score: -135.98

MedTech

Recs

2
Member Avatar Kdhard1 (< 20) Submitted: 5/4/2012 12:10:11 PM : Outperform Start Price: $8.41 CLSN Score: -121.08

Let me start by saying this is a speculative play. Celsion currently is in Phase III of their clinical trial for treatment for liver cancer and Phase II for breast cancer. The stock has pulled well back from its highs but has held stable at its current level. I hope to see a run up over the next several months in anticipation of the phase III clinical trial being completed in the 4th quarter of 2012.

Recs

0
Member Avatar antigalu (< 20) Submitted: 11/4/2011 9:11:53 PM : Outperform Start Price: $15.98 CLSN Score: -149.47

The drugs 600 patient interim analysis should prove to be a positive catalyst over the near term. A license deal should be in the near term also, if successful results occur. Not a big if IMHO!

Recs

0
Member Avatar rodessa (38.90) Submitted: 10/1/2011 9:00:45 AM : Outperform Start Price: $11.11 CLSN Score: -162.01

Coming soon, agreement of new treatment both in europe and in the US

Recs

0
Member Avatar investwhenever (< 20) Submitted: 7/30/2011 1:37:40 AM : Outperform Start Price: $17.82 CLSN Score: -144.21

Spec play, like dndn was, I like it..

Recs

0
Member Avatar Distressedstar (< 20) Submitted: 7/11/2011 8:46:23 PM : Outperform Start Price: $16.07 CLSN Score: -141.66

0.5

Recs

2
Member Avatar riciulius (< 20) Submitted: 4/14/2011 3:18:06 PM : Outperform Start Price: $9.90 CLSN Score: -131.98

Second giant killer that is in my 20-20-20 bucket (over 20% insider, under 20 PE, within 20% of 52 week low).

Look at the insider trades... they have been upping the ante significantly with each phase of the trial completed. These guys are industry vets (check the resumes) and they obviously believe that they are going to knock this out of the park. This is a ridiculously low valuation for this stock given the phase of the trial and the large market for this interesting therapy.

Oh, and their patent was approved recently, so there seems to be a tight plan by management with final FDA approval set to come down the pipe soon.

Recs

0
Member Avatar whomonkyoulus (28.48) Submitted: 10/25/2010 6:01:53 PM : Outperform Start Price: $13.64 CLSN Score: -155.57

Insiders seem to think that their results are worth betting on at this price.

Results 1 - 14 of 14

Featured Broker Partners


Advertisement